Molecular biological and genetic investigations of cancers in companion animals: impact on veterinary care and comparative value for (rare) cancers in the human.

Gerard R Rutteman
Utrecht University Clinic of Companion Animals
Veterinary Specialist Center de Wagenrenk
NL

#### Framework for comparative research

- Standardized record keeping
- Standard pathological classification (WHO)
- Storage of DNA, plasma/serum
- Storage of tissue (rapid freezing, RNA-later, FFPE-blocks)
- Collection of DNA from healthy veterans
- Development of specific cell lines

Dedicated to Professor Wim Misdorp 1929-2009



#### Progestins in the Dog may lead to:

Increased Growth Hormone production in mammary tissue: Potential role in mammary tumorigenesis



Gustave Courbet con negro perro



#### GH in mammary tumorigenesis

GH mRNA and protein in mammary tissue & tumors

- dog, cat, human (Mol, Rutteman, ea, 1994-1999)

Progestin-induced GH stimulates proliferation of stem cells in human breast epithelium

(Lombardi ea, 2014)

#### Osteosarcoma in the dog

- Most appendicular
- Highly metastatic (>95%)
- Large breeds predisposed
   (Great Dane, Irish Wolfhound, St Bernard, Leonberger, Rottweiler, etc)

Growth / GH permissive factor?

#### Recognition of risk for MH (HS) in BMD

- Moore & Rosin, Vet Pathol, 1984
- NL: Schmidt, Rutteman, Van Niel, Wolvekamp, Vet Q, 1994

#### Value of comparative research in dog/cat

- May be of use to the human
- Chance to increase financial support. . .
- For HS research in BMD, my estimate of funding: 10% veterinary resources, 90% human (at present >> 10 million Euro)


# Visceral HS - Often multifocal lung, liver, spleen



#### **Cancer Predisposition in Bernese Mountain Dog**

- Life time risk for malignant histiocytic tumours may be 15-20% (Erich, e.a., 2013)
- Excess >500x (compared to other breeds)





#### Visceral HS (earlier "MH")

- Spleen, liver, lung, BM
- Rapid multifocal development

#### Review initial tumor diagnosis in FCR & BMD

- Selection of records from 4 labs in NL + Cambridge in UK
- Pathology (n=894) and cytology (n=396)
- Revision including IHC
- ➤ Of cases with HS (1st diagnosis) 75% confirmed.

(Erich et al, 2018)

Tumor often near joint: Non-visceral HS

- Destructive
- Highly metastatic



#### Follow up of Veterans (BMD / FCR)

- Data and DNA collected at 8 years or older
- 164 BMD
- 6 dogs developed HS
- 34 developed cancer (in 1/3 suspicion of HS)
- Thus: 1/4 eliminated from genetic analysis
- 40 lost to follow up.

#### HS in other organs

- Kidney,
- Stomach, intestine
- Skin (differentiate form SH)
- Head & Neck
- Bladder
- CNS
- Lymph nodes (metastatic?)

### Potential association of HS risk with other cancers

- Hemangiosarcoma (concurrent in some families)
- Mal. Lymphoma (concurrent in individual dogs)

#### Risk of mammary cancer

"The population-based incidence rates (for all ages) of malignant mammary tumours per 1000 female dogs per year were 35.47 in boxers, 3.87 in Bernese mountain dog"

L. Moe, J Reprod Fertil, 57 (suppl) 2001

What protects BMD from mammary cancer?

#### Gene expression in histiocytic sarcomas

STHS: primary tumor soft tissue often near joints / tendons; metastasis in most dogs < 1 year

VHS: primary tumor visceral organs, often multiple and generalized at 1st presentation; metastasis in most dogs < 4 months

(Dobson J, 2009; Erich SA et al, 2013)

## Potential factors influencing mammary cancer (MC) risk

- Function endocrine system?
- Function immune system

What if factors predisposing for HS protect from MC?

#### Gene expression in histiocytic sarcomas

- Fresh-frozen tissue from FCR with HS (STHS and VHS; CD18 confirmed)
- Normal canine spleens → RNA extraction
- Microarray analysis and pathway analyses
- Confirmation using quantitative real-time PCR (qPCR) analyses



Flatcoated Retriever: also predisposed for histiocytic sarcoma

#### Comparison of HS - Spleen

319 Probes differentially expressed (P<0.05) when 4-fold changes or larger were taking into account.

Altered expression of nine genes confirmed by qPCR.

- Down-regulated : PPBP, SpiC, VCAMI, ENPEP, ITGAD
- Up-regulated: GTSF1, Col3a1, CD90, LUM (Boerkamp et al, 2014)

PPBP also downregulated in human myeloma

#### Comparing HS/ Spleen

DAVID pathway analyses revealed various pathways that were significantly involved in the development of HS in general, most of which were involved in the DNA repair and replication process.

#### (Dys)function of disease genes

 Knowledge of function of genes involved in diseases such as HS, improves the chance of just intervention (prevention / treatment)

#### Comparing VHS/ STHS

191 Probes were significantly differentially expressed

QPCR confirmed the significantly altered expression of three genes.

- Up-regulated: C6

- Down-regulated: CLEC12A, CCL5

CLEC12A: cell adhesion, negative regulator of granulocyte and monocyte function

#### Thanks

- To all dog owners that contributed
- And to collaborating breed societies
- And funding organizations:
   KWF, St DOG, EC, DRC, FRC, VBSH, NBSV, NLRV, SSV, RCS

Albert Heim Stiftung

#### Translation of expression studies in cancer

- Immune-histochemistry / proteomics
- Functional assays
- Tumor stroma (ECM) interactions
- Comparison with human cancers

#### **Exposition Art Drager Meurtant**

Kunstwerk! Liemers Museum, Zevenaar, NL, June 16 – September 9 2016



### HS in Bernese Mountain Dog

MTAP-CDKN2A disease allele:

Cases: homozygote 65%, heterozygote 31% Controls: homozygote 24%, heterozygote 60% Major difference, not yet sufficient to use for selection

Also at CFA14 there is significance, but less so in USA: European BMDs must provide the answer

#### Histiocytic sarcomas in FCR

Preliminary results of GWAS (NIH)

- Locus MH/HS in BMD: not relevant
- Two genomic regions highly significant variation between cases and controls: ongoing.